Overview A Study of LY2189102 in Patients With Type 2 Diabetes Status: Completed Trial end date: 2010-11-01 Target enrollment: Participant gender: Summary Study to evaluate the safety, tolerability and efficacy of LY2189102 in patients with type 2 diabetes. Phase: Phase 2 Details Lead Sponsor: Eli Lilly and Company